enoblituzumab   Click here for help

GtoPdb Ligand ID: 9589

Synonyms: MGA-271 | MGA271
Immunopharmacology Ligand
Compound class: Antibody
Comment: Enoblituzumab (MGA271) is a humanized IgG1κ mAb with enhanced ADCC. Its target is the B7-H3 (CD276) member of the B7 family of immune regulators [2]. It has been engineered to enhance effector-mediated antitumor function via increased affinity for the activating receptor CD16A (FcγRIII) and decreased binding to the inhibitory receptor CD32B (FcγRIIB).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST sequence analysis identifies exact matches with antibody peptides claimed in patent US8802091, and specifically with a construct designated as hBRCA84D-2 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Enoblituzumab (MGA271) is an oncology clinical candidate. It was advanced to clinical trials for a number of advanced solid tumours, either as a monotherapy or in combination with established immune checkpoint inhibitor mAbs. In July 2022, MacroGenics closed their phase 2 clinical trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN; NCT04634825), after 7 study participants (out of 62) died potentially as the result of adverse hemorrhagic events, a rate that is higher than would be expected in patients with SCCHN. They also withdrew their phase 2/3 SCCHN study NCT04129320 before recruitment began.
Click here to link to a list of MGA271 trials registered at ClinicalTrials.gov.